Clinical management of progressive myopia

Abstract

Myopia has been increasing in prevalence throughout the world, reaching over 90% in some East Asian populations. There is increasing evidence that whereas genetics clearly have an important role, the type of visual environment to which one is exposed to likely influences the onset, progression, and cessation of myopia. Consequently, attempts to either modify the environment or to reduce the exposure of the eye to various environmental stimuli to eye growth through the use of various optical devices are well under way at research centers around the globe. The most promising of current treatments include low-percentage atropine, bifocal soft contact lenses, orthokeratology, and multifocal spectacles. These methods are discussed briefly and are then categorized in terms of their expected degree of myopia progression control. A clinical strategy is presented for selecting the most effective treatment for the appropriate type of patient at the optimal stage of refractive development to achieve the maximum control of myopia progression.

Corneal Reshaping and Wavefront Aberrations During Overnight Orthokeratology

“…32 The effectiveness on reducing the progression of the myopia was related to the retinal image quality. 32 The effectiveness on reducing the progression of the myopia was related to the retinal image quality.…”

IMI – Clinical Management Guidelines Report

“…9,61,[233][234][235] Treatments are likely to be most effective at younger ages when rapid progression is underway, and the efficacy of some treatments may wane after the first 6 months to 2 years of treatment. 62,72,172,184,236 Further research is required to fully support clinicians in determining when to cease an individual's treatment and the relative importance of factors such as age, ethnicity, rate of progression, and level of myopia when making this decision.…”

Genetic prediction of myopia: prospects and challenges

“…Appeals have been made for eye care professionals to start prescribing anti‐myopia therapies as part of their routine management of myopic children . These calls are fuelled by two key considerations.…”